Anti-VEGF Treatment for Prevention of PDR/DME
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 322
Summary
- Conditions
- Diabetic Macular Edema
- Diabetic Retinopathy
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02634333
- Collaborators
- Regeneron Pharmaceuticals
- Juvenile Diabetes Research Foundation
- National Eye Institute (NEI)
- National Institutes of Health (NIH)
- Investigators
- Study Chair: Jennifer K. Sun, MD, MPH Joslin Diabetes Center